Targeting tumor-associated acidity in cancer immunotherapy Ruben LacroixElisa A. RozemanChristian U. Blank Review 05 July 2018 Pages: 1331 - 1348
Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab Carlo PutzuDiego Luigi CortinovisPanagiotis Paliogiannis Commentary 09 June 2018 Pages: 1349 - 1353
mTOR-mediated glycolysis contributes to the enhanced suppressive function of murine tumor-infiltrating monocytic myeloid-derived suppressor cells Yuting DengJiao YangYiwei Chu Original Article 02 July 2018 Pages: 1355 - 1364
Peripheral monocytes and neutrophils predict response to immune checkpoint inhibitors in patients with metastatic non-small cell lung cancer Kaushal ParikhArun KumarSeah H. Lim Original Article 02 July 2018 Pages: 1365 - 1370
Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette–Guerin for patients with non-muscle invasive bladder cancer Wataru ObaraIsao HaraTomoaki Fujioka Original Article 03 July 2018 Pages: 1371 - 1380
Potentiation of PD-L1 blockade with a potency-matched dual cytokine–antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains Roberto De LucaDario Neri Original Article 04 July 2018 Pages: 1381 - 1391
Levels of peripheral blood polymorphonuclear myeloid-derived suppressor cells and selected cytokines are potentially prognostic of disease progression for patients with non-small cell lung cancer Lourdes BarreraEdgar Montes-ServínOscar Arrieta Original Article 04 July 2018 Pages: 1393 - 1406
Anti-ADAM17 monoclonal antibody MEDI3622 increases IFNγ production by human NK cells in the presence of antibody-bound tumor cells Hemant K. MishraNabendu PoreBruce Walcheck Original Article 05 July 2018 Pages: 1407 - 1416
Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC Nobuko MatsuuraGenju KohMasanori Emoto Original Article 11 July 2018 Pages: 1417 - 1424
Naturally produced type I IFNs enhance human myeloid dendritic cell maturation and IL-12p70 production and mediate elevated effector functions in innate and adaptive immune cells Annette E. SköldTill S. M. MathanI. Jolanda M. de Vries Original Article Open access 13 July 2018 Pages: 1425 - 1436
Production of a mouse monoclonal IgM antibody that targets the carbohydrate Thomsen-nouveau cancer antigen resulting in in vivo and in vitro tumor killing Kevin R. TrabbicKristopher A. KleskiPeter R. Andreana Original Article 20 July 2018 Pages: 1437 - 1447
CD11c+ MHCIIlo GM-CSF-bone marrow-derived dendritic cells act as antigen donor cells and as antigen presenting cells in neoepitope-elicited tumor immunity against a mouse fibrosarcoma Hakimeh Ebrahimi-NikWilliam L. CorwinPramod K. Srivastava Original Article Open access 20 July 2018 Pages: 1449 - 1459
Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma Tessa GargettM. Nazim AbbasMichael P. Brown Clinical Trial Report 16 July 2018 Pages: 1461 - 1472
“Pseudoprogression”: more than semantics Janice P. Dutcher Letter to the Editors 18 July 2018 Pages: 1473 - 1474
Reply to “Pseudoprogression”: more than semantics Alvin S. WongMartin B. Lee Letter to the Editors 30 July 2018 Pages: 1475 - 1475
Correction to: High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer Yusuke OkumaTsunekazu HishimaSadamu Homma Correction 06 August 2018 Pages: 1477 - 1479
